Literature DB >> 29608957

ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors.

Shahrukh K Hashmi1, Stephanie J Lee2, Bipin N Savani3, Linda Burns4, John R Wingard5, Miguel-Angel Perales6, Jeanne Palmer7, Eric Chow8, Everett Meyer9, David Marks10, Mohamad Mohty11, Yoshihiro Inamoto12, Cesar Rodriguez13, Arnon Nagler14, Craig Sauter6, Krishna V Komanduri15, Joseph Pidala16, Mehdi Hamadani17, Laura Johnston9, Nina Shah18, Paul Shaughnessy19, Betty K Hamilton20, Navneet Majhail20, Mohamed A Kharfan-Dabaja21, Jeff Schriber22, Zachariah DeFilipp23, Katherine G Tarlock24, Suzanne Fanning25, Peter Curtin26, J Douglas Rizzo18, Paul A Carpenter27.   

Abstract

Significant advances in hematopoietic cell transplantation (HCT) have increased the long-term survivorship of its recipients, but because of unique complications arising from radiation and chemotherapy, recipients require lifelong follow-up. To evaluate current survivorship or long-term follow-up (LTFU) clinics specifically for HCT survivors and to evaluate the potential barriers in their establishment, the American Society for Blood and Marrow Transplantation (ASBMT) Practice Guidelines Committee electronically surveyed 200 HCT programs to gather quantitative and qualitative data about models of care. Among 77 programs (38.5%) that responded, 45% indicated presence of an LTFU clinic; however, LTFU care models varied with respect to services provided, specialist availability, type of patients served, and staffing. Among 55% of programs without an LTFU clinic, 100% agreed that allogeneic HCT survivors have unique needs separate from graft-versus-host disease and that complications could arise during the transition of care either from pediatric to adult settings or away from the HCT center. Lack of expertise, logistics, financial issues, and the observation that 84% of individual practitioners prefer to provide survivorship care were the identified obstacles to establishing new LTFU clinics. The ASBMT hopes that policymakers, HCT providers, and institutions will benefit from the results of this survey and recommends that delivering guidelines-driven screening and expert management of late effects is the goal of first-rate HCT survivorship care.
Copyright © 2018 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Long-term; Survivor; Transplant

Mesh:

Year:  2018        PMID: 29608957     DOI: 10.1016/j.bbmt.2018.03.023

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  6 in total

1.  Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia.

Authors:  Catherine J Lee; Soyoung Kim; Heather R Tecca; Stephanie Bo-Subait; Rachel Phelan; Ruta Brazauskas; David Buchbinder; Betty K Hamilton; Minoo Battiwalla; Navneet S Majhail; Hillard M Lazarus; Peter J Shaw; David I Marks; Mark R Litzow; Saurabh Chhabra; Yoshihiro Inamoto; Zachariah DeFilipp; Gerhard C Hildebrandt; Richard F Olsson; Kimberly A Kasow; Jane L Liesveld; Seth J Rotz; Sherif M Badawy; Neel S Bhatt; Jean A Yared; Kristin M Page; Martha L Arellano; Michael Kent; Nosha Farhadfar; Sachiko Seo; Peiman Hematti; César O Freytes; Alicia Rovó; Siddhartha Ganguly; Sunita Nathan; Linda Burns; Bronwen E Shaw; Lori S Muffly
Journal:  Blood Adv       Date:  2020-03-24

2.  Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy.

Authors:  Catherine J Lee; Tao Wang; Karen Chen; Mukta Arora; Ruta Brazauskas; Stephen R Spellman; Carrie Kitko; Margaret L MacMillan; Joseph A Pidala; Jeffery J Auletta; Sherif M Badawy; Neel Bhatt; Vijaya R Bhatt; Jean-Yves Cahn; Zachariah DeFilipp; Miguel A Diaz; Nosha Farhadfar; Shahinaz Gadalla; Robert P Gale; Hasan Hashem; Shahrukh Hashmi; Peiman Hematti; Sanghee Hong; Nasheed M Hossain; Yoshihiro Inamoto; Lazaros J Lekakis; Dipenkumar Modi; Sager Patel; Akshay Sharma; Scott Solomon; Daniel R Couriel
Journal:  Transplant Cell Ther       Date:  2022-07-18

3.  Development and Implementation of an Advanced Practitioner-Led Survivorship Clinic for Patients Status Post Allogeneic Transplant.

Authors:  Linda K Baer; Lauren Brister; Susan R Mazanec
Journal:  J Adv Pract Oncol       Date:  2021-11-01

4.  Long-term transplant outcomes after allogeneic hematopoietic transplant in pediatric patients with hematological malignancies are influenced by severe chronic graft vs. host disease and immune reconstitution.

Authors:  Blanca Molina; Marta González-Vicent; Ivan Lopez; Alba Pereto; Julia Ruiz; Manuel Ramirez; Miguel A Díaz
Journal:  Front Pediatr       Date:  2022-08-12       Impact factor: 3.569

5.  Pulmonary surveillance in pediatric hematopoietic stem cell transplant: A multinational multidisciplinary survey.

Authors:  Shivanthan Shanthikumar; William A Gower; Matthew Abts; Deborah R Liptzin; Elizabeth K Fiorino; Anne Stone; Saumini Srinivasan; Timothy J Vece; Nour Akil; Theresa Cole; Kenneth R Cooke; Samuel B Goldfarb
Journal:  Cancer Rep (Hoboken)       Date:  2021-07-28

6.  Driving Distance and Patient-Reported Outcomes in Hematopoietic Cell Transplantation Survivors.

Authors:  Rahul Banerjee; Jean C Yi; Navneet S Majhail; Heather S L Jim; Joseph Uberti; Victoria Whalen; Alison W Loren; Karen L Syrjala
Journal:  Biol Blood Marrow Transplant       Date:  2020-08-08       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.